Becton Dickinson and Company (BDX)

NYSE
240.54
+0.29(+0.12%)
After Hours
240.02
-0.52(-0.22%)
- Real-time Data
  • Volume:
    2,561,604
  • Bid/Ask:
    237.17/244.39
  • Day's Range:
    238.79 - 242.61

BDX Overview

Prev. Close
240.25
Day's Range
238.79-242.61
Revenue
18.86B
Open
239.34
52 wk Range
219.5-284.97
EPS
5.62
Volume
2,561,604
Market Cap
69.95B
Dividend (Yield)
3.32
(1.38%)
Average Vol. (3m)
1,402,653
P/E Ratio
42.81
Beta
0.77
1-Year Change
1.24%
Shares Outstanding
290,818,504
Next Earnings Date
Aug 12, 2021
What is your sentiment on Becton Dickinson and Company?
or
Market is currently closed. Voting is open during market hours.

Becton Dickinson and Company News

Becton Dickinson and Company Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellNeutral
Technical IndicatorsSellSellBuyStrong SellSell
SummaryStrong SellStrong SellNeutralStrong SellNeutral

Becton Dickinson and Company Company Profile

Becton Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Read More
  • anyone an idea for a target?
    0
    • $240
      0
  • https://www.fool.com/investing/2021/02/27/these-3-stocks-big-winners-from-president-biden/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
    0
    • Last chance to get in , DPA will give a big boost in a few weeks.
      1
      • Rajeesh Raju good luck
        0
      • Lode Schepershttps://www.nasdaq.com/articles/becton-dickinson-gets-eua-for-new-diagnostic-test-2021-02-14
        0
      • Rajeesh Raju Thank you very much. Succes!
        0
    • bye bye b d x you stepped on Elon Musk toes
      2
      • what happened ?
        0
    • https://www.biospace.com/article/releases/cardiff-oncology-prices-public-offering-sep-30-2020/
      0
      • 300$ by end of 2020
        1
        • We need to see at least 230 before its worth getting into.
          2
          • insane earnings, insane share price, insane P/E ratio
            0
            • P/E isn't insane, 91 is without NRI, forward P/E is 20. At 15 it would be a good entry point but the price would have to be $180.
              0
          • . I want to know if this asset comes in at 192 this week? What do you guys think?
            0
            • I would pull the trigger at $180 with a forward P/E of 15.
              0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.